Literature DB >> 17600596

A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination.

Juliana Cassataro1, Karina A Pasquevich, Silvia M Estein, Diego A Laplagne, Astrid Zwerdling, Silvia de la Barrera, Raúl Bowden, Carlos A Fossati, Guillermo H Giambartolomei, Fernando A Goldbaum.   

Abstract

In the present study, we reported an attempt to improve the immunogenicity and protective capacity of the chimera BLSOmp31 using a different antigen delivery: DNA vaccination. Vaccination of BALB/c mice with the DNA vaccine coding for the chimera BLSOmp31 (pCIBLSOmp31) provided the best protection level against Brucella ovis, which was significantly higher than the given by the co-delivery of both plasmids coding for the whole proteins (pcDNABLS+pCIOmp31) and even higher than the control vaccine Rev.1. Moreover, pCIBLSOmp31 induced higher protection against Brucella melitensis than pcDNABLS+pCIOmp31 but similar protection than Rev.1. The chimera induced a strong humoral response against the inserted peptide. It also induced peptide- and BLS-specific cytotoxic T responses. The insertion of this peptide on BLS induced stronger T helper 1 responses specific for the carrier (BLS), thus our results represent a case of synergic strengthening between two Brucella antigens. Hitherto, this is the first indication that a recombinant subunit vaccine elicits greater protection than whole Brucella.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600596     DOI: 10.1016/j.vaccine.2007.05.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Putative ATP-binding cassette transporter is essential for Brucella ovis pathogenesis in mice.

Authors:  Teane M A Silva; Tatiane A Paixão; Erica A Costa; Mariana N Xavier; Joicy Cortez Sá; Valéria S Moustacas; Andreas B den Hartigh; Alcina V Carvalho Neta; Sérgio C Oliveira; Renée Tsolis; Renato L Santos
Journal:  Infect Immun       Date:  2011-02-07       Impact factor: 3.441

2.  An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice.

Authors:  Karina A Pasquevich; Andrés E Ibañez; Lorena M Coria; Clara García Samartino; Silvia M Estein; Astrid Zwerdling; Paula Barrionuevo; Fernanda S Oliveira; Christine Seither; Heribert Warzecha; Sergio C Oliveira; Guillermo H Giambartolomei; Juliana Cassataro
Journal:  PLoS One       Date:  2011-01-14       Impact factor: 3.240

3.  Mutants in the lipopolysaccharide of Brucella ovis are attenuated and protect against B. ovis infection in mice.

Authors:  Pedro Soler-Lloréns; Yolanda Gil-Ramírez; Ana Zabalza-Baranguá; Maite Iriarte; Raquel Conde-Álvarez; Amaia Zúñiga-Ripa; Beatriz San Román; Michel S Zygmunt; Nieves Vizcaíno; Axel Cloeckaert; María-Jesús Grilló; Ignacio Moriyón; Ignacio López-Goñi
Journal:  Vet Res       Date:  2014-07-17       Impact factor: 3.683

4.  Meta-Analysis and Advancement of Brucellosis Vaccinology.

Authors:  Tatiane F Carvalho; João Paulo A Haddad; Tatiane A Paixão; Renato L Santos
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

5.  Immunoreactivity evaluation of a new recombinant chimeric protein against Brucella in the murine model.

Authors:  Abbas Abdollahi; Shahla Mansouri; Jafar Amani; Mahdi Fasihi-Ramandi; Mohammad Moradi
Journal:  Iran J Microbiol       Date:  2016-06

6.  Diagnostic potential of Brucella melitensis Rev1 native Omp28 precursor in human brucellosis.

Authors:  Ismail Koyuncu; Abdurrahman Kocyigit; Ahmet Ozer; Sahabettin Selek; Adnan Kirmit; Hasan Karsen
Journal:  Cent Eur J Immunol       Date:  2018-03-30       Impact factor: 2.085

Review 7.  Second career of a biosynthetic enzyme: Lumazine synthase as a virus-like nanoparticle in vaccine development.

Authors:  Rudolf Ladenstein; Ekaterina Morgunova
Journal:  Biotechnol Rep (Amst)       Date:  2020-07-06

8.  Efficient Immunization of BALB/c Mice against Pathogenic Brucella melitensis and B. ovis: Comparing Cell-Mediated and Protective Immune Responses Elicited by pCDNA3.1 and pVAX1 DNA Vaccines Coding for Omp31 of Brucella melitensis.

Authors:  Naser Harzandi; Haniyeh Aghababa; Nima Khoramabadi; Termeh Tabaraie
Journal:  Iran J Biotechnol       Date:  2021-01-01       Impact factor: 1.671

Review 9.  When the Going Gets Rough: The Significance of Brucella Lipopolysaccharide Phenotype in Host-Pathogen Interactions.

Authors:  Lauren W Stranahan; Angela M Arenas-Gamboa
Journal:  Front Microbiol       Date:  2021-07-15       Impact factor: 5.640

10.  Evaluation in mice of Brucella ovis attenuated mutants for use as live vaccines against B. ovis infection.

Authors:  Pilar Sancho; Carmen Tejedor; Rebeca S Sidhu-Muñoz; Luis Fernández-Lago; Nieves Vizcaíno
Journal:  Vet Res       Date:  2014-06-04       Impact factor: 3.683

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.